November 19, 2022

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/Madam,

Sub : Completion of US FDA Inspection at our Unit IX – Reg.,
Ref : Our Letter dated May 17, 2019

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and further to our above referred letter, this is to inform you that:

The United States Food and Drug Administration (US FDA) inspected the Company's Unit - IX, an intermediate facility situated at Gundlamachnoor Village, Sangareddy District, Telangana, from November 10 to November 18, 2022.

The said Unit had been classified as OAI on May 17, 2019 and the Company had responded to the agency and carried out the required corrective actions. The US FDA Authorities have reinspected the facility as mentioned above.

At the end of the inspection, the Company has been issued a 'Form 483' with 10 observations. In our view, these observations are procedural in nature and not related to data integrity. The Company will respond to the US FDA, within the stipulated timeline and shall work closely with the agency to address the observations at the earliest.

We will keep the stock exchanges further informed if there is any material information relating to the above in the future.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

ADIREDDY BADDIGAM
Digitally signed by ADIREDDY BADDIGAM
Date: 2022.11.19 11:10:03 +05'30'

B. Adi Reddy
Company Secretary